Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co. Ltd., announced the launch of cyclosporine ophthalmic emulsion 0.05%, the therapeutic equivalent to the reference listed drug, cyclosporine ophthalmic emulsion 0.05% (Restasis; Allergan, an AbbVie company). Bora received US Food and Drug Administration (FDA) approval of its abbreviated new drug application for the product in January 2026.

The product is available in 30-count and 60-count 0.4 mL single-use vials

"The launch of cyclosporine ophthalmic emulsion reflects Upsher-Smith's continued momentum in expanding and diversifying its US portfolio," said Jim Maahs, senior vice president, head of Upsher-Smith Commercial. "This addition strengthens our ophthalmic offerings and reflects our focus on bringing medicines to market that support the evolving needs of our customers, health care providers, and patients." OM